NORMALIZATION OF HEMATOCRIT IN HEMODIALYSIS PATIENTS WITH CARDIAC DISEASE DOES NOT INCREASE BLOOD PRESSURE

REFERENCES

• Berglund B, Ekblom B. Effect of recombinant human erythropoietin treatment on blood pressure and some hematological parameters in healthy men. Journal of Internal Medicine 1991; 229: 125–130
   PubMed Web of Science ®Google Scholar
• Carlini R, Chamberlain I O, Rosthein M. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. American Journal of Hypertension 1993; 6: 103–107
   PubMed Web of Science ®Google Scholar
• Clinical Y, Imai Y, Sekino H, Fujikura Y, Munakata M, Minami N, Hashimoto J, Sakuma H, Watanabe N, Miasawa S, Nishiyama A, Abe K. Pressor effect of recombinant human erythropoietin; results of ambulatory bllod pressure monitoring and home blood pressure measurements. Clinical and Experimental Hypertension 1995; 17: 485–506
   PubMed Web of Science ®Google Scholar
• Conlon P, Walshe J J, Heinle S K, Minda S, Krucoff M, Schwab S J. Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J Am Soc Nephrol 1996; 7: 2658–2663
   PubMed Web of Science ®Google Scholar
• Conlon P J, Carmody M, O'Donnell R, Spencer R, Donohoe J, Walshe J J. Treatment of end stage renal failure patients with recombinant erythropoietin: One centre's experience. Irish Journal of Medical Sciences 1993; 163: 17–19
   Google Scholar
• Eschbach J W, Egrie J C, Downing M R, Browne J K, Adamson J W. Correction of the anemia of end stage renal disease with recombinant human erythropoietin, Results of a combined phase 1 and phase II clinical trial. New England Journal of Medicine 1987; 316: 73–78
   PubMed Web of Science ®Google Scholar
• Hand M F, Haynes W G, Johnstone H A, Anderton J L, Webb D J. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney International 1995; 48: 806–813
   PubMed Web of Science ®Google Scholar
• Ishimitsu T, Tsukada H, Ogawa Y, Numabe A, Yagi S. Genetic Predisposition to Hypertension Facilities blood pressure elevation in hemodialysis patients treated with erythropioetin. The American Journal of Medicine 1993; 94: 401–406
   PubMed Web of Science ®Google Scholar
• Jones M A, Kingswood J C, Dallyn P E, Andrew M, Cheetham A, Burwood R, Sharpstone P. Changes in diurnal blood pressure variation and red cell and plasma volumes in patients with renal failure who develop erythropoietin-induced hypertension. Clin Nephrol 1995; 44: 193–200
   PubMed Web of Science ®Google Scholar
• Lebel M, Grose J H, Kingma I, Langlois S. Plasma endothelin levels and blood pressure in hemodialysis and in CAPD patyients. Effect of subcutaneous erythropoietin replacement therapy. Clinical Experimental Hypertension 1994; 16: 565–575
   PubMed Web of Science ®Google Scholar
• Maschio G. Erythropoietin and systemic hypertension. Nephrol Dial Transplant 1995; 10(Suppl 2)74–79
   PubMed Web of Science ®Google Scholar
• Pincus T, Olsen N J, Russell I J, Wolfe F, Harris E R, Schnitzer T J, Boccagno J A, Krantz S B. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. American Journal of Medicine 1990; 89: 161–168
   PubMed Web of Science ®Google Scholar
• Roger S D, Grasty M S, Baker L R, Raine A E. Effects of oxygen breathing and erythropoietin on hypoxic vasodilation in uremic anemia. Kidney International 1992; 42: 975–980
   PubMed Web of Science ®Google Scholar
• Takahashi S, Yanai M, Okada K. Recombinant human erythropoietin has no direct or strong vasoconstrictor effects in vivo and in vitro. Nephrol Dial Transplant 1995; 10: 815–820
   PubMed Web of Science ®Google Scholar
• Besarab A, Bolton W K, Browne J K, Egrie J C, Nissenson A R, Okamoto D M, Schwab S J, Goodkin D A. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and poietin. New England Journal of Medicine 1998; 339: 584–590
   PubMed Web of Science ®Google Scholar
• van de Borne P, Tielemans C, Vanherweghem J L, Degaute J P. Effect of recombinant human erythropoietin therapy on ambulatory blood pressure and heart rate in chronic haemodialysis patients. Nephrol Dial Transplant 1992; 7: 45–49
   PubMed Web of Science ®Google Scholar
• Winearls C G, Pippard M J, Downing M R, Oliver D O, Reid C, Cotes P M. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic hemodialysis. Lancet 1986; 1–7
   Web of Science ®Google Scholar